Southeast Asia Breast Cancer Therapeutics Market 2022 Southeast Asia Breast Cancer Therapeutics Market

Southeast Asia Breast Cancer Therapeutics
Market will be valued at $2.7 billion in 2022:
Radiant Insights, Inc
“The breast cancer Southeast Asian market will be
valued at $2.7 billion in 2022, growing from $942.3m
in 2015 at a CAGR of 16.2%.”
Summary
Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are
invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts
of the body through the bloodstream and the lymphatic system. Broadly, patients can be
segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment
and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has
had a worse overall survival than HER2-negative disease, which is considered less aggressive.
In HER2-negative breast cancer, a number of different factors can influence the choice of therapy
that a patient receives, including the stage of the cancer, the hormonal receptor status of the
cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-
mutation carrier.
Browse Complete Summary Click Here @
http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-southeast-
asia-markets-to-2022
Follow Us: